false Q3 --12-31 0001468929 0001468929 2024-01-01 2024-09-30 0001468929 NXGL:CommonStockParValue0.001Member 2024-01-01 2024-09-30 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0001468929 2024-11-13 0001468929 2024-09-30 0001468929 2023-12-31 0001468929 2024-07-01 2024-09-30 0001468929 2023-07-01 2023-09-30 0001468929 2023-01-01 2023-09-30 0001468929 us-gaap:CommonStockMember 2023-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-12-31 0001468929 us-gaap:RetainedEarningsMember 2023-12-31 0001468929 us-gaap:CommonStockMember 2024-03-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001468929 us-gaap:NoncontrollingInterestMember 2024-03-31 0001468929 us-gaap:RetainedEarningsMember 2024-03-31 0001468929 2024-03-31 0001468929 us-gaap:CommonStockMember 2024-06-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001468929 us-gaap:NoncontrollingInterestMember 2024-06-30 0001468929 us-gaap:RetainedEarningsMember 2024-06-30 0001468929 2024-06-30 0001468929 us-gaap:CommonStockMember 2022-12-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001468929 us-gaap:NoncontrollingInterestMember 2022-12-31 0001468929 us-gaap:RetainedEarningsMember 2022-12-31 0001468929 2022-12-31 0001468929 us-gaap:CommonStockMember 2023-03-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-03-31 0001468929 us-gaap:RetainedEarningsMember 2023-03-31 0001468929 2023-03-31 0001468929 us-gaap:CommonStockMember 2023-06-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001468929 us-gaap:NoncontrollingInterestMember 2023-06-30 0001468929 us-gaap:RetainedEarningsMember 2023-06-30 0001468929 2023-06-30 0001468929 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001468929 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001468929 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001468929 2024-01-01 2024-03-31 0001468929 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001468929 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001468929 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001468929 2024-04-01 2024-06-30 0001468929 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001468929 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001468929 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001468929 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001468929 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001468929 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001468929 2023-01-01 2023-03-31 0001468929 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001468929 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001468929 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001468929 2023-04-01 2023-06-30 0001468929 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001468929 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001468929 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001468929 us-gaap:CommonStockMember 2024-09-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001468929 us-gaap:NoncontrollingInterestMember 2024-09-30 0001468929 us-gaap:RetainedEarningsMember 2024-09-30 0001468929 us-gaap:CommonStockMember 2023-09-30 0001468929 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001468929 us-gaap:NoncontrollingInterestMember 2023-09-30 0001468929 us-gaap:RetainedEarningsMember 2023-09-30 0001468929 2023-09-30 0001468929 NXGL:JointVentureMember 2023-03-01 0001468929 NXGL:CGLabsMember 2023-03-01 0001468929 NXGL:EnigmaHealthJointVentureMember 2023-01-06 0001468929 NXGL:MoietyMember 2023-01-06 0001468929 NXGL:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2024-11-11 2024-11-11 0001468929 NXGL:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2024-11-11 0001468929 2023-01-01 2023-12-31 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2024-07-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:ContractManufacturingMember 2024-07-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:ContractManufacturingMember 2024-07-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2024-07-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2024-07-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2024-07-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2024-07-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:BrandedConsumerProductsMember 2024-07-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:BrandedConsumerProductsMember 2024-07-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2024-07-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:OtherIncomesMember 2024-07-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:OtherIncomesMember 2024-07-01 2024-09-30 0001468929 NXGL:NexgelMember 2024-07-01 2024-09-30 0001468929 NXGL:CGNJVMember 2024-07-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember 2024-07-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2023-07-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:ContractManufacturingMember 2023-07-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:ContractManufacturingMember 2023-07-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-07-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-07-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-07-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2023-07-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:BrandedConsumerProductsMember 2023-07-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:BrandedConsumerProductsMember 2023-07-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2023-07-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:OtherIncomesMember 2023-07-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:OtherIncomesMember 2023-07-01 2023-09-30 0001468929 NXGL:NexgelMember 2023-07-01 2023-09-30 0001468929 NXGL:CGNJVMember 2023-07-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember 2023-07-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2024-01-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:ContractManufacturingMember 2024-01-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:ContractManufacturingMember 2024-01-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2024-01-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2024-01-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2024-01-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2024-01-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:BrandedConsumerProductsMember 2024-01-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:BrandedConsumerProductsMember 2024-01-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2024-01-01 2024-09-30 0001468929 NXGL:CGNJVMember NXGL:OtherIncomesMember 2024-01-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:OtherIncomesMember 2024-01-01 2024-09-30 0001468929 NXGL:NexgelMember 2024-01-01 2024-09-30 0001468929 NXGL:CGNJVMember 2024-01-01 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember 2024-01-01 2024-09-30 0001468929 NXGL:NexgelMember NXGL:ContractManufacturingMember 2023-01-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:ContractManufacturingMember 2023-01-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:ContractManufacturingMember 2023-01-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:CustomAndWhiteLabelFinishedGoodsMember 2023-01-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:BrandedConsumerProductsMember 2023-01-01 2023-09-30 0001468929 NXGL:NexgelMember NXGL:OtherIncomesMember 2023-01-01 2023-09-30 0001468929 NXGL:CGNJVMember NXGL:OtherIncomesMember 2023-01-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember NXGL:OtherIncomesMember 2023-01-01 2023-09-30 0001468929 NXGL:NexgelMember 2023-01-01 2023-09-30 0001468929 NXGL:CGNJVMember 2023-01-01 2023-09-30 0001468929 us-gaap:ReportableSubsegmentsMember 2023-01-01 2023-09-30 0001468929 NXGL:NexgelMember 2024-09-30 0001468929 NXGL:CGNJVMember 2024-09-30 0001468929 us-gaap:ReportableSubsegmentsMember 2024-09-30 0001468929 NXGL:NexgelMember 2023-12-31 0001468929 NXGL:CGNJVMember 2023-12-31 0001468929 us-gaap:ReportableSubsegmentsMember 2023-12-31 0001468929 NXGL:SillyGeorgeAcquisitionMember 2024-05-15 2024-05-15 0001468929 NXGL:SillyGeorgeAcquisitionMember 2024-05-15 0001468929 NXGL:KenkodermAcquisitionMember 2023-12-01 2023-12-01 0001468929 NXGL:KenkodermAcquisitionMember 2023-12-01 0001468929 NXGL:MembershipInterestPurchaseAgreementMember NXGL:SportsDefenseAcquisitionMember 2020-05-29 2020-05-29 0001468929 NXGL:MembershipInterestPurchaseAgreementMember NXGL:SportsDefenseAcquisitionMember 2020-05-29 0001468929 NXGL:MembershipInterestPurchaseAgreementMember NXGL:SportsDefenseAcquisitionMember NXGL:MrAdamLevyMember 2020-05-29 2020-05-29 0001468929 NXGL:MembershipInterestPurchaseAgreementMember NXGL:SportsDefenseAcquisitionMember NXGL:MrNachumSteinMember 2020-05-29 2020-05-29 0001468929 NXGL:CGLaboratoriesIncMember 2023-03-01 0001468929 2023-03-01 2023-03-01 0001468929 NXGL:MoietyMember 2023-01-06 0001468929 NXGL:EnigmaHealthJointVentureMember 2024-09-30 0001468929 NXGL:SillyGeorgeAcquisitionMember 2024-01-01 2024-09-30 0001468929 NXGL:KenkodermAcquisitionMember 2024-01-01 2024-09-30 0001468929 NXGL:SportsDefenseAcquisitionMember 2024-01-01 2024-09-30 0001468929 NXGL:CGLabsMember 2024-01-01 2024-09-30 0001468929 NXGL:SportsDefenseAcquisitionMember 2020-05-29 2020-05-29 0001468929 NXGL:SportsDefenseAcquisitionMember 2020-05-29 0001468929 NXGL:CGLabsMember 2023-03-01 2023-03-01 0001468929 NXGL:KenkodermAndSillyGeorgeAcquisitionMember 2024-01-01 2024-09-30 0001468929 NXGL:KenkodermAndSillyGeorgeAcquisitionMember 2023-01-01 2023-09-30 0001468929 country:PA 2024-01-01 2024-09-30 0001468929 us-gaap:PropertyPlantAndEquipmentMember 2024-09-30 0001468929 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001468929 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001468929 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2024-09-30 0001468929 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2024-09-30 0001468929 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001468929 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001468929 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2024-09-30 0001468929 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2024-09-30 0001468929 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001468929 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001468929 us-gaap:ConstructionInProgressMember 2024-09-30 0001468929 us-gaap:ConstructionInProgressMember 2023-12-31 0001468929 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-09-30 0001468929 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:CustomerRelatedIntangibleAssetsMember 2024-09-30 0001468929 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-12-31 0001468929 us-gaap:TradeNamesMember 2024-09-30 0001468929 us-gaap:TradeNamesMember 2023-12-31 0001468929 us-gaap:TrademarksMember 2024-01-01 2024-09-30 0001468929 us-gaap:TrademarksMember 2024-09-30 0001468929 us-gaap:TrademarksMember 2023-12-31 0001468929 us-gaap:MarketingRelatedIntangibleAssetsMember 2024-09-30 0001468929 us-gaap:MarketingRelatedIntangibleAssetsMember 2023-12-31 0001468929 NXGL:SportDefenseLlcMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2020-05-29 0001468929 NXGL:CGLabsJVMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2023-03-01 0001468929 NXGL:KenkodermMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2023-12-01 0001468929 NXGL:SillyGeorgeAcquisitionMember NXGL:TechnologyRelatedAndCustomerRelatedIntangiblesMember 2024-05-15 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-08-08 2024-08-08 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-08-08 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:CommonStockMember 2024-08-08 2024-08-08 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:WarrantMember 2024-08-08 2024-08-08 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember srt:MinimumMember 2024-08-08 2024-08-08 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember srt:MaximumMember 2024-08-08 2024-08-08 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember NXGL:NonAffiliatedEntityMember 2024-08-08 2024-08-08 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember srt:AffiliatedEntityMember 2024-08-08 2024-08-08 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-08-08 2024-08-08 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-08-08 0001468929 NXGL:ConsultantMember 2024-06-06 2024-06-06 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:CommonStockMember 2024-02-15 2024-02-15 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember us-gaap:WarrantMember 2024-02-15 2024-02-15 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember srt:MinimumMember 2024-02-15 2024-02-15 0001468929 NXGL:RegisteredDirectOfferingMember NXGL:SubscriptionAgreementsMember srt:MaximumMember 2024-02-15 2024-02-15 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember NXGL:NonAffiliatedEntityMember 2024-02-15 2024-02-15 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember srt:AffiliatedEntityMember 2024-02-15 2024-02-15 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 2024-02-15 0001468929 NXGL:PlacementAgentMember NXGL:SubscriptionAgreementsMember 2024-02-15 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2020-05-26 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-05-03 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2021-05-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-03-23 2023-03-23 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember srt:ExecutiveOfficerMember 2023-03-23 2023-03-23 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2024-09-30 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-09-30 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember srt:MinimumMember 2024-01-01 2024-09-30 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember srt:MaximumMember 2024-01-01 2024-09-30 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2024-01-01 2024-01-01 0001468929 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2024-01-01 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2024-09-30 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2024-01-01 2024-09-30 0001468929 NXGL:AwardsGrantedOutsideOfThe2019PlanMember 2024-09-30 0001468929 NXGL:AwardsGrantedOutsideOfThe2019PlanMember 2024-01-01 2024-09-30 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2023-12-31 0001468929 NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001468929 us-gaap:StockOptionMember NXGL:TwoThousandAndNineteenLongTermIncentivePlanMember 2024-01-01 2024-09-30 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001468929 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001468929 NXGL:OriginallyReportedMember 2023-12-31 0001468929 NXGL:OriginallyReportedMember 2023-01-01 2023-12-31 0001468929 NXGL:WarrantsTwoThousandTwentyOneInitialPublicOfferingMember 2024-01-01 2024-01-01 0001468929 NXGL:JVNotesPayableMember 2024-09-30 0001468929 NXGL:JVNotesPayableMember 2024-03-13 2024-03-13 0001468929 NXGL:JVNotesPayableMember 2024-03-13 0001468929 NXGL:JVNotesPayableMember 2023-12-31 0001468929 NXGL:JVNotesPayableMemberOneMember 2024-09-30 0001468929 NXGL:JVNotesPayableMemberOneMember 2024-02-29 0001468929 NXGL:JVNotesPayableMemberOneMember 2023-12-31 0001468929 NXGL:JVNotesPayableMemberOneMember 2024-03-13 2024-03-13 0001468929 NXGL:JVNotesPayableMemberOneMember 2024-03-13 0001468929 NXGL:NexgelMember 2024-09-30 0001468929 NXGL:NexgelMember 2024-02-11 2024-02-11 0001468929 NXGL:NexgelMember 2024-02-11 0001468929 NXGL:EconomicInjuryDisasterLoanMember 2020-05-28 0001468929 NXGL:EconomicInjuryDisasterLoanMember 2020-05-27 2020-05-28 0001468929 us-gaap:PrivatePlacementMember 2021-09-02 0001468929 us-gaap:PrivatePlacementMember 2021-03-11 0001468929 us-gaap:PrivatePlacementMember 2021-02-03 0001468929 us-gaap:PrivatePlacementMember 2020-12-24 0001468929 us-gaap:PrivatePlacementMember 2020-03-18 0001468929 us-gaap:PrivatePlacementMember 2019-09-10 0001468929 us-gaap:PrivatePlacementMember 2019-11-06 0001468929 srt:MinimumMember us-gaap:PrivatePlacementMember 2024-09-30 0001468929 srt:MaximumMember us-gaap:PrivatePlacementMember 2024-09-30 0001468929 us-gaap:WarrantMember 2023-12-31 0001468929 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001468929 us-gaap:WarrantMember 2024-09-30 0001468929 srt:MinimumMember us-gaap:WarrantMember 2024-09-30 0001468929 srt:MaximumMember us-gaap:WarrantMember 2024-09-30 0001468929 srt:MinimumMember us-gaap:WarrantMember 2023-09-30 0001468929 srt:MaximumMember us-gaap:WarrantMember 2023-09-30 0001468929 us-gaap:WarrantMember 2023-09-30 0001468929 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001468929 srt:MinimumMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001468929 srt:MaximumMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001468929 srt:MinimumMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001468929 srt:MaximumMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001468929 NXGL:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001468929 NXGL:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001468929 NXGL:OtherCustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001468929 NXGL:OtherCustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001468929 NXGL:OtherCustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001468929 NXGL:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001468929 NXGL:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:OtherCustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:OtherCustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:OtherCustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001468929 NXGL:Dr.JeromeZeldisMember 2023-12-31 0001468929 NXGL:ScottRHenryMember 2024-07-01 2024-09-30 0001468929 NXGL:AdamRLevyMember 2024-07-01 2024-09-30 0001468929 NXGL:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2024-11-13 2024-11-13 0001468929 NXGL:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2024-11-13 0001468929 NXGL:SubscriptionAgreementsMember us-gaap:SubsequentEventMember NXGL:AlereFinancialPartnersLLCMember 2024-11-11 2024-11-11 0001468929 NXGL:SubscriptionAgreementsMember us-gaap:SubsequentEventMember NXGL:AlereFinancialPartnersLLCMember 2024-11-11 0001468929 NXGL:ScottRHenryMember 2024-09-30 0001468929 NXGL:AdamRLevyMember 2024-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2024

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission file number: 001-41173

 

NexGel, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   26-4042544
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification Number)

 

2150 Cabot Blvd West, Suite B

Langhorne, PA

  19047
(Address of principal executive office)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 702-8550

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer  
  Smaller reporting company Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of November 13, 2024, the registrant had 6,790,777 shares of common stock outstanding.

 

 

 

 
 

 

nEXGEL, INC.

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION
 
ITEM 1. Condensed Consolidated Financial Statements (Unaudited) 3
  Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 3
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 4
  Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023 5
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 7
  Notes to Condensed Consolidated Financial Statements 8
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 28
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 36
ITEM 4. Controls and Procedures 36
     
  PART II – OTHER INFORMATION  
ITEM 1. Legal Proceedings 37
ITEM 1A. Risk Factors 37
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 37
ITEM 3. Defaults Upon Senior Securities 37
ITEM 4. Mine Safety Disclosures 37
ITEM 5. Other Information 37
ITEM 6. Exhibits 38
     
Signatures 39

 

2
Table of Contents 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

NEXGEL, INC

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023

(Unaudited)

(in thousands, except share and per share data)

 

   September 30, 2024   December 31, 2023 
ASSETS:          
Current Assets:          
Cash and cash equivalents  $1,059   $2,700 
Accounts receivable, net   894    633 
Inventory   1,778    1,319 
Prepaid expenses and other current assets   879    400 
Total current assets   4,610    5,052 
Goodwill   1,124    1,128 
Intangibles, net   839    326 
Property and equipment, net   2,219    1,499 
Operating lease - right of use asset   1,685    1,855 
Other assets   95    95 
Total assets  $10,572   $9,955 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Accounts payable  $1,505   $1,233 
Accrued expenses and other current liabilities   609    398 
Deferred revenue   179    20 
Current portion of note payable   83    80 
Warrant liability   109    146 
Contingent consideration liability   271    439 
Financing lease liability, current portion   58    - 
Operating lease liabilities, current portion   234    233 
Total current liabilities   3,048    2,549 
Operating lease liabilities, net of current portion   1,589    1,727 
Financing lease liability, net of current portion   323    - 
Notes payable, net of current portion   626    513 
Total liabilities   5,586    4,789 
           
Commitments and Contingencies (Note 16)   -       
           
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding   -    - 
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 6,790,777 and 5,741,838 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively   7    6 
Additional paid-in capital   21,826    19,406 
Accumulated deficit   (17,146)   (14,715)
Total NexGel stockholders’ equity   4,687    4,697 
Non-controlling interest in joint venture   299    469 
Total stockholders’ equity   4,986    5,166 
Total liabilities and stockholders’ equity  $10,572   $9,955 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3
Table of Contents 

 

NEXGEL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Unaudited)

(in thousands, except share and per share data)

 

   2024   2023   2024   2023 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2024   2023   2024   2023 
Revenues, net  $2,940   $1,221   $5,647   $3,007 
                     
Cost of revenues   1,658    877    3,678    2,546 
                     
Gross profit   1,282    344    1,969    461 
                     
Operating expenses                    
Research and development   -    6    78    90 
Selling, general and administrative   2,070    950    4,604    2,629 
Total operating expenses   2,070    956    4,682    2,719 
                     
Loss from operations   (788)   (612)   (2,713)   (2,258)
                     
Other income (expense)                    
Interest expense   (20)   (3)   (67)   (13)
Interest income   -    1    2    3 
Other income   39    -    40    3 
Gain on investments   5    44    62    168 
Changes in fair value of warrant liability   10    18    37    96 
Total other income, net   34    60    74    257 
Loss before income taxes   (754)   (552)   (2,639)   (2,001)
Income tax expense   -    -    -    - 
Net loss  $(754)  $(552)  $(2,639)  $(2,001)
Less: Loss (income) attributable to non-controlling interest in joint venture   61    2    208    (58)
Net loss attributable to NexGel stockholders   (693)   (550)   (2,431)   (2,059)
Net loss per common share - basic  $(0.11)  $(0.10)  $(0.39)  $(0.36)
Net loss per common share - diluted  $(0.11)  $(0.10)  $(0.39)  $(0.36)
Weighted average shares used in computing net loss per common share - basic   6,569,403    5,714,316    6,274,221    5,654,981 
Weighted average shares used in computing net loss per common share – diluted   6,569,403    5,714,316    6,274,221    5,654,981 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4
Table of Contents 

 

NEXGEL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024

(Unaudited)

(in thousands, except share data)

 

   Shares   Amount   Capital   Interest   Deficit   Equity 
   Common Stock  

Additional

Paid-in

  

Non-

controlling

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Interest   Deficit   Equity 
Balance, January 1, 2024   5,741,838   $6   $19,406   $469   $(14,715)  $5,166 
                               
Share-based compensation and restricted stock vesting           54            54 
                               
Equity offering proceeds, net of expenses   485,786        946            946 
                               
Issuance of placement agent warrants in conjunction with the equity offering           (56)           (56)
                               
Net loss               (52)   (853)   (905)
                               
Balance, March 31, 2024   6,227,624   $6   $20,350   $417   $(15,568)  $5,205 
                               
Share-based compensation and restricted stock vesting   1,750        55            55 
                               
Shares issued in acquisition   89,892        200            200 
                               
Issuance of shares for services   5,000        9            9 
                               
Non-controlling interest contribution               37        37 
                               
Net loss               (94)   (885)   (979)
                               
Balance, June 30, 2024   6,324,266   $6   $20,614   $360   $(16,453)  $4,527 
                               
Share-based compensation and restricted stock vesting   22,511        154            154 
                               
Equity offering proceeds, net of expenses   444,000    1    1,002            1,003 
                               
Issuance of placement agent warrants in conjunction with the equity offering           56           56
                               
Net loss               (61)   (693)   (754)
                               
Balance, September 30, 2024   6,790,777   $7   $21,826   $299   $(17,146)  $4,986 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5
Table of Contents 

 

NEXGEL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023

(Unaudited)

(in thousands, except share data)

 

   Common Stock  

Additional

Paid-in

  

Non-

controlling

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Interest   Deficit   Equity 
Balance, January 1, 2023   5,577,916   $6   $19,189   $-   $(11,558)  $7,637 
                               
Restricted stock vesting   5,682    -    24    -    -    24 
                               
Exercise of warrants   30,430    -    -    -    -    - 
                               
Non-controlling interest in JV   -    -    -    500    -    500 
                               
Net income (loss)   -    -    -    7    (814)   (807)
                               
Balance, March 31, 2023   5,614,028   $6   $19,213   $507   $(12,372)  $7,354 
                               
Stock-based compensation   -    -    29    -    -    29 
                               
Exercise of warrants   82,036    -    -    -    -    - 
                               
Net income (loss)   -    -    -    53    (695)   (642)
                               
Balance, June 30, 2023   5,696,064   $6   $19,242   $560   $(13,067)  $6,741 
                               
Stock-based compensation   21,565    -    67    -    -    67 
                               
Net income (loss)   -    -    -    (2)   (550)   (552)
                               
Balance, September 30, 2023   5,717,629   $6   $19,309   $558   $(13,617)  $6,256 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6
Table of Contents 

 

NEXGEL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Unaudited)

(in thousands)

 

   2024   2023 
  

Nine Months Ended

September 30,

 
   2024   2023 
Operating Activities          
Net loss  $(2,431)  $(2,059)
Adjustments to reconcile net loss to net cash used in operating activities:          
Income (loss) attributable to non-controlling interest in joint venture   (208)   58 
Depreciation and amortization   328    103 
Changes in ROU asset and operating lease liability   31    33 
Share-based compensation and restricted stock vesting   271    120 
Gain on investment in marketable securities   (62)   168 
Changes in fair value of warrant liability   (37)   (96)
           
Changes in operating assets and liabilities:          
Accounts receivable   (261)   (936)
Inventory   (459)   (588)
Prepaid expenses and other assets   (479)   (227)
Accounts payable   272    808 
Accrued expenses and other current liabilities   (132)   (67)
Deferred revenue   159    34 
Net Cash Used in Operating Activities   (3,008)   (2,649)
           
Investing Activities          
Proceeds from sales of marketable securities   62    5,340 
Capital expenditures   (374)   (611)
Net cash paid for Asset acquisition   (400)   - 
Net Cash (Used in) Provided by Investing Activities   (712)   4,729 
           
Financing Activities          
Proceeds from margin line of credit   345    89 
Proceeds from Rights offering   1,950     
Investment by joint venture partner   37      
Principal payment on financing lease liability   (36)    
Change in contingent consideration liability   (164)    
Principal payments of notes payable   (53)   (4)
Net Cash Provided by Financing Activities   2,079    85 
Net Decrease in Cash   (1,641)   2,165 
Cash – Beginning of period   2,700    1,101 
Cash – End of period  $1,059   $3,266 
Supplemental Disclosure of Cash Flows Information          
Cash paid during the year for:          
Interest  $65   $7 
Taxes  $   $ 
           
Supplemental Non-cash Investing and Financing activities          
Shares issued in conjunction with asset acquisition  $200   $ 
Property and equipment financed under notes payable  $165   $ 
Property and equipment financed under financing leases  $416   $ 
Property and equipment contributed as capital investment to JV  $   $500 
ROU asset and operating lease liabilities recognized upon consolidation of JV  $   $334 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7
Table of Contents 

 

NEXGEL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

 

1. Description of Business, Stock Split and Basis of Presentation

 

NexGel, Inc. (“NexGel” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the Company. First, we launched our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, the Company and its customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture.

 

NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019.

 

On May 15, 2024, the Company purchased substantially all of the assets from Semmens Online Pty Ltd as Trustee for Semmens Business Trust (the “SG Seller”) related to the SG Seller’s eyeliner, fake eyelashes, lash serum and mascara business operating under the tradename “Silly George” (collectively, the “Silly George Business”).

 

On December 1, 2023, the Company purchased substantially all of the assets Olympus Trading Company, LLC (the “Kenkoderm Seller”) related to the Kenkoderm Seller’s skincare line focused on reducing symptoms associated with psoriasis operating under the tradename “Kenkoderm” (“Kenkoderm acquisition”).

 

On March 1, 2023, the Company acquired a 50% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC (“CGN”), with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business. The JV is effective March 1, 2023. As a result of this transaction, the Company owns 50% of the JV, with the remaining 50% held by CG Labs.

 

On January 6, 2023, the Company acquired a 50% interest in a newly formed JV (“Enigma”) to pursue branded consumer product retail opportunities and the development of new patch products. The JV agreement is effective January 6, 2023. As a result of this transaction, the Company owns 50% of the JV, with the remaining 50% held by Moiety.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements and footnotes of NexGel have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of the Company and its condensed consolidated wholly-owned subsidiary, NexGelRx, Inc. and the fifty percent (50%) owned JV’s (see Note 5).

 

2. Going Concern

 

As of September 30, 2024, the Company had a cash balance of $1.1 million. For the nine months ended September 30, 2024, the Company incurred a net loss of $2.4 million and had a net usage of cash in operating activities of $3.0 million. In addition, the Company had a working capital of $1.6 million as of September 30, 2024.

 

8
Table of Contents 

 

On November 11, 2024, the Company entered into subscription agreements with investors and certain members of its board of directors and management for the sale by the Company of an aggregate of 363,636 units at a price to the public of $5.50 per unit, with each unit consisting of two shares of the Company’s common stock, and a warrant to purchase one share of common stock at an exercise price of $4.25 per share (the “November Financing”). The November Financing is expected to close on or about November 13, 2024 with gross proceeds to the Company expected to be $2.0 million, before deducting the placement agent’s fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the warrants. The Company intends to use the net proceeds from the RDO for working capital and for general corporate purposes (discussed further within Note 19).

 

Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices. The Company has increased focus on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.

 

We intend to maintain and attempt to grow our existing contract manufacturing business. We also plan to continue building and developing our catalogue of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media and online advertising and marketplaces. Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology. Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.

 

We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the condensed consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.

 

3. Significant Accounting Policies and Estimates

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for credit losses, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.

 

Reclassifications

 

We have reclassified, combined or separately disclosed certain amounts in the prior years’ consolidated financial statements and accompanying footnotes to conform with the current year’s presentation.

 

Segment Reporting

 

The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, Segment Reporting, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company has two reportable segments - the NexGel segment and the “CGN” segment.

 

The NexGel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. The NexGel segment includes the Kenkoderm and Silly George recent acquisitions and the Enigma JV.

 

9
Table of Contents 

 

The “CGN” segment is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.

 

Cash and cash equivalents

 

Cash and cash equivalents is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.

 

Margin Line of Credit

 

The Company has a brokerage account through which it can buy and sell U.S. treasury bills. The provisions of the account allow us to borrow on certain securities held in the account and to purchase additional securities based on the account equity (including cash). Amounts borrowed are collateralized by the securities held in the account and bear interest at a negotiated rate payable monthly. Securities pledged to secure margin balances cannot be specifically identified as a portion of all securities held in a brokerage account are used as collateral. As of September 30, 2024 and December 31, 2023, there was $345 thousand and $245 thousand outstanding under this short-term credit line which is included in accrued expenses and other current liabilities within the accompanying condensed consolidated balance sheet. The short-term credit line will be repaid upon the maturity of U.S. treasury bills of $0.8 million with an original maturity of three months or less which are included in cash within the accompanying consolidated balance sheet (see Note 11).

 

Accounts Receivable, net

 

Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for credit losses based on factors including the length of time the receivables are past due, the customer’s payment history, the credit quality of the customer and other factors that may affect the customers’ ability to pay. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for credit losses was $19 thousand as of September 30, 2024 and $11 thousand as of December 31, 2023.

 

Inventory and Cost of Revenues

 

The inventory balance is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value.

 

The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.

 

The inventory balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses and at fulfilment centers owned by Amazon, Walmart and CVS.

 

The “Cost of revenues” line item in the condensed consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.

 

Research and Development

 

Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.

 

10
Table of Contents 

 

Property and Equipment, net

 

Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.

 

Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.

 

The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.

 

Impairment of Long-Lived Assets

 

The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.

 

Goodwill and Intangible Assets

 

In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of the acquisition date or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value.

 

The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and no impairments were recognized in the year ended December 31, 2023.

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets are recorded at historical cost and are primarily made up of $65 thousand and $64 thousand of prepaid insurance, and $814 thousand and $336 thousand general prepaid expenses and other current assets as of September 30, 2024 and December 31, 2023, respectively.

 

Other Assets

 

Other assets are recorded at historical costs, and as of September 30, 2024 and December 31, 2023, the balance is primarily comprised of spare parts for manufacturing equipment. The Company maintains spare for either repair and maintenance, which is expensed as incurred, or replacement of capitalized equipment. Capitalized equipment spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.

 

11
Table of Contents 

 

Fair Value Measurements

 

The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

Level 1 —Quoted prices for identical assets or liabilities in active markets.

 

Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.

 

The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the condensed consolidated balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.

 

Warrant Liability

 

Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2024. The fair values of the warrants are estimated as of the date of issuance and again at each reporting period using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the condensed consolidated statements of operations.

 

Equity Classified Warrants

 

Warrants that meet all necessary criteria to be accounted for as equity in accordance with ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity are presented within additional paid-in capital within Company’s condensed consolidated statements of changes in stockholders’ equity and condensed consolidated balance sheets. Warrants classified as equity are initially measured at fair value. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified as equity.

 

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

 

The Company currently recognizes revenue predominately from three sources, contract manufacturing, custom and white label finished goods manufacturing (“Custom and white label”), and our branded consumer products. Contract manufacturing and Custom and white label revenues are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product. Branded consumer product revenue is derived from direct-to-consumer purchases through websites like Amazon and through our Shopify stores. Revenue is recognized upon shipment to the end customer.

 

The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are predominately concentrated in the United States, but with the Silly George acquisition, have expanded into Europe and Asia. Payment terms, excluding branded consumer products, vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Branded consumer products are purchased and paid for by the consumer at the time the transaction is completed.

 

Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.

 

12
Table of Contents 

 

Disaggregated revenue by sales type ($ in thousands):

 

   2024   2023 
   Three months ended 
   September 30, 
   2024   2023 
Contract manufacturing  $864   $805 
Custom and white label   -    5 
Branded consumer products   1,930    356 
Medical devices/other   146    55 
Total  $2,940   $1,221 

 

   2024   2023 
   Nine months ended 
   September 30, 
   2024   2023 
Contract manufacturing  $1,890   $2,072 
Custom and white label   42    10 
Branded consumer products   3,515    850 
Medical devices/other   200    75 
Total  $5,647   $3,007 

 

As of September 30, 2024 and December 31, 2023, the Company did not have any contract assets or contract liabilities from contracts with customers and there were no remaining performance obligations that the Company had not satisfied except for deferred revenue of $179 and $20 at September 30, 2024 and December 31, 2023, respectively, that the Company had not satisfied as of the end of the respective period.

 

The Company has four distinct lines of business; Contract Manufacturing, Custom and White Label, Branded Consumer Products, and Medical Devices/Other.

 

Contract Manufacturing

 

Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they package into finished goods. Historically, this has been the Company’s primary source of revenue.

 

Custom and White Label

 

These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into saleable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product. Custom and white label revenue is recognized upon delivery of the finished product.

 

Branded Consumer Products

 

These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. When merchandise is shipped to a customer, our performance obligation is met, and revenue is recognized when control passes to the customer. These products carry the Company’s brand names, which include Medagel, Lumagel Beauty, Kenkoderm and Silly George.

 

Medical Devices/Other

 

Medical Devices are a hybrid business, combining elements of Custom and White Label and Branded Consumer Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.

 

Other includes shipping and handling revenue from customers who purchase the Company’s branded consumer products through their Shopify stores. It also includes a small amount of freight revenue from contract manufacturing customers.

 

Shipping and Handling Revenue and Expense

 

Shipping and handling revenue and expense are included in our condensed consolidated statements of operations in revenues and cost of revenues, respectively. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control passes to the customer. Shipping revenue and expense are primarily generated through the Amazon marketplace and Silly George direct customer sales.

 

Share-based Compensation

 

On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 13 below for further details regarding the 2019 Plan.

 

13
Table of Contents 

 

The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the condensed consolidated statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the condensed consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the condensed consolidated financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.

 

Leases

 

ASC 842, Leases, requires recognition of leases on the condensed consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.

 

The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.

 

Variable Interest Entity

 

The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.

 

14
Table of Contents 

 

If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s condensed consolidated financial statements. As of December 31, 2023, and on a quarterly basis thereafter, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.

 

Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s condensed consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial position or results of operations upon adoption.

 

In June 2016, the FASB issued Accounting Standards Update (“ASU’) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023 and subsequent interim periods. The Company adopted this new standard during the year ended December 31, 2023 and it did not have a material impact to its condensed consolidated financial statements.

 

Accounting Pronouncements Issued But Not Yet Adopted

 

In June 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-05, Business Combinations (ASC Topic 805): Joint Venture Formations, which provides guidance on accounting for joint ventures established through new entities. The update mandates the application of the acquisition method of accounting for such transactions, requiring parties to recognize and measure identifiable assets and liabilities based on fair values at the acquisition date and establishes a measurement period for adjustments. The amendments in this Update are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. ASU 2023-05 will be effective for non-public entities for annual periods beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the implications of this update on its accounting practices for joint ventures and expects it will enhance consistency and transparency in financial reporting, without a material impact on its financial position or results of operations.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced income tax related disclosures. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the Company being required to include enhanced disclosures relating to its reportable segments. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

 

15
Table of Contents 

 

4. Business Segments

 

The Company’s CODM evaluates the financial performance of the Company’s segments based upon segment adjusted operating income or (loss) as the profitability measure. Items outside of adjusted operating income or (loss) are not reported by segment, since they are excluded from the single measure of segment profitability reviewed by the CODM.

 

Summarized financial information concerning the Company’s reportable segments for each of the quarters ended September 30, 2024 and 2023 is presented below.

 

For Quarter Ended September 30, 2024 ($ in thousands)

 

   NexGel   CGN JV   Total 
Revenue               
Contract Manufacturing  $396   $468   $864 
Custom and White Label Finished Goods   -    -    - 
Branded Consumer Products   1,930    -    1,930 
Other income   109    37    146 
Total revenue   2,435    505    2,940 
                
Cost of sales   1,155    503    1,658 
Operating expenses   1,873    197    2,070 
Loss from operations  $(593)  $(195)  $(788)

 

For Quarter Ended September 30, 2023 ($ in thousands)

 

   NexGel   CGN JV   Total 
Revenue               
Contract Manufacturing  $223   $582   $805 
Custom and White Label Finished Goods   5    -    5 
Branded Consumer Products   356    -    356 
Other income   53    2    55 
Total revenue   637    584    1,221 
                
Cost of sales   444    433    877 
Operating expenses   799    157    956 
Loss from operations  $(606)  $(6)  $(612)

 

16
Table of Contents 

 

For the Nine Months Ended September 30, 2024 ($ in thousands)